FDA panel votes down Abbott's cancer drug

An FDA advisory panel unanimously recommended disapproval of Abbott Laboratories' prostate cancer drug Xinlay, citing studies showing the drug failed to halt the cancer's advance. However, some members of the committee said they believed the drug could help certain patients.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA